Recently, a novel biomarker, differentially methylated circulating DNA, has become a research hotspot. It has better sensitivity and specificity in the detection of beta cell death.
Differentially methylated circulating DNA is being studied as minimally invasive biomarker of cell death. We aimed to explore whether the unmethylated/methylated ratio of the insulin and amylin genes might be a good biomarker of cell death in different types of diabetes. View all Here, we demonstrate the versatility of MeD-seq, a methylation-dependent sequencing assay, for comprehensive cfDNA analysis, including DNA methylation profiling, chromosomal copy number... Circulating tumor DNA (ctDNA) methylation, an innovative liquid biopsy biomarker, has emerged as a promising tool in early cancer diagnosis, monitoring, and prognosis prediction. As a noninvasive approach, liquid biopsy overcomes the limitations of traditional tissue biopsy. Differentially methylated circulating DNA: A novel biomarker to monitor beta cell death Understanding how DNA methylation is associated with hypertension progression across mid-to-late adulthood could improve mechanistic insight and support the identification of biomarkers and therapeutic targets that vary with age. Introduction The significance of aberrant DNA methylation in cancer and other diseases has become increasingly clear over the past decade [1, 2]. DNA methylation markers are being used in cancer diagnosis, prognosis, and monitoring [3, 4]. Identification and tracking of differentially methylated DNA in cancer samples and liquid biopsies are commonly used as cancer biomarkers, similar to cancer ...
Here, we demonstrate the versatility of MeD-seq, a methylation-dependent sequencing assay, for comprehensive cfDNA analysis, including DNA methylation profiling, chromosomal copy number...
Circulating tumor DNA (ctDNA) methylation, an innovative liquid biopsy biomarker, has emerged as a promising tool in early cancer diagnosis, monitoring, and prognosis prediction. As a noninvasive approach, liquid biopsy overcomes the limitations of traditional tissue biopsy.
Introduction The significance of aberrant DNA methylation in cancer and other diseases has become increasingly clear over the past decade [1, 2]. DNA methylation markers are being used in cancer diagnosis, prognosis, and monitoring [3, 4]. Identification and tracking of differentially methylated DNA in cancer samples and liquid biopsies are commonly used as cancer biomarkers, similar to cancer ...
